Organization
Double Bond Pharmaceutical
1 clinical trial
Clinical trial
An Open-label Dose Escalation Study to Estimate MTD, Identify DLTs and Study Pharmacokinetics Following a Single Dose of Intracranially Administered Temozolomide-based SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GlioblastomaStatus: Not yet recruiting, Estimated PCD: 2025-07-01